SE9701409D0 - Treatment of rheumatoid arthritis - Google Patents

Treatment of rheumatoid arthritis

Info

Publication number
SE9701409D0
SE9701409D0 SE9701409A SE9701409A SE9701409D0 SE 9701409 D0 SE9701409 D0 SE 9701409D0 SE 9701409 A SE9701409 A SE 9701409A SE 9701409 A SE9701409 A SE 9701409A SE 9701409 D0 SE9701409 D0 SE 9701409D0
Authority
SE
Sweden
Prior art keywords
treatment
rheumatoid arthritis
pharmaceutical composition
arthritic
comp
Prior art date
Application number
SE9701409A
Other languages
English (en)
Inventor
Dick Heinegaard
Lars Klareskog
Johnny Lorentzon
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9701409A priority Critical patent/SE9701409D0/sv
Publication of SE9701409D0 publication Critical patent/SE9701409D0/sv
Priority to CA002286791A priority patent/CA2286791A1/en
Priority to SK1413-99A priority patent/SK141399A3/sk
Priority to CN98806210A priority patent/CN1260721A/zh
Priority to HU0002231A priority patent/HUP0002231A3/hu
Priority to TR1999/02564T priority patent/TR199902564T2/xx
Priority to AU70938/98A priority patent/AU746221B2/en
Priority to AT98917896T priority patent/ATE245438T1/de
Priority to EEP199900464A priority patent/EE9900464A/xx
Priority to IDW991208A priority patent/ID24561A/id
Priority to IL13235498A priority patent/IL132354A0/xx
Priority to PL98336163A priority patent/PL336163A1/xx
Priority to BR9808591-3A priority patent/BR9808591A/pt
Priority to PCT/SE1998/000682 priority patent/WO1998046253A1/en
Priority to EP98917896A priority patent/EP1019078B1/en
Priority to NZ338084A priority patent/NZ338084A/en
Priority to JP54382098A priority patent/JP2001520647A/ja
Priority to KR1019997009437A priority patent/KR20010006352A/ko
Priority to DE69816634T priority patent/DE69816634T2/de
Priority to IS5210A priority patent/IS5210A/is
Priority to NO995004A priority patent/NO995004L/no
Priority to US09/750,208 priority patent/US20010002392A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE9701409A 1997-04-15 1997-04-15 Treatment of rheumatoid arthritis SE9701409D0 (sv)

Priority Applications (22)

Application Number Priority Date Filing Date Title
SE9701409A SE9701409D0 (sv) 1997-04-15 1997-04-15 Treatment of rheumatoid arthritis
DE69816634T DE69816634T2 (de) 1997-04-15 1998-04-14 Verwendung von oligomerem matrixprotein aus knorpel zur behandlung von rheumatoider arthritis
IL13235498A IL132354A0 (en) 1997-04-15 1998-04-14 Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis
BR9808591-3A BR9808591A (pt) 1997-04-15 1998-04-14 Uso de proteìna de matriz oligomérica de cartilagem para o tratamento de artrite reumatóide.
CN98806210A CN1260721A (zh) 1997-04-15 1998-04-14 用低聚软骨基质蛋白治疗类风湿性关节炎
HU0002231A HUP0002231A3 (en) 1997-04-15 1998-04-14 Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis
TR1999/02564T TR199902564T2 (xx) 1997-04-15 1998-04-14 K�k�rdak oligomer matris proteininin romatoid artrit tedavisinde kullan�m�.
AU70938/98A AU746221B2 (en) 1997-04-15 1998-04-14 Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis
AT98917896T ATE245438T1 (de) 1997-04-15 1998-04-14 Verwendung von oligomerem matrixprotein aus knorpel zur behandlung von rheumatoider arthritis
EEP199900464A EE9900464A (et) 1997-04-15 1998-04-14 Kõhre maatriksi oligomeerse valgu kasutamine reumatoidartriidi raviks
IDW991208A ID24561A (id) 1997-04-15 1998-04-14 Pemakaian protein matriks oligomerik kartilaj untuk mengobati artritis rematoid
CA002286791A CA2286791A1 (en) 1997-04-15 1998-04-14 Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis
PL98336163A PL336163A1 (en) 1997-04-15 1998-04-14 Application of oligomeric cartilage intercellular substance protein in treating rheumatologic arthritis
SK1413-99A SK141399A3 (en) 1997-04-15 1998-04-14 Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis
PCT/SE1998/000682 WO1998046253A1 (en) 1997-04-15 1998-04-14 Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis
EP98917896A EP1019078B1 (en) 1997-04-15 1998-04-14 Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis
NZ338084A NZ338084A (en) 1997-04-15 1998-04-14 Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis
JP54382098A JP2001520647A (ja) 1997-04-15 1998-04-14 リュウマトイド関節炎の処置用軟骨オリゴマーマトリクスタンパク質の使用
KR1019997009437A KR20010006352A (ko) 1997-04-15 1998-04-14 류머티즘성 관절염의 치료에 있어서 올리고머형 연골 매트릭스 단백질의 용도
IS5210A IS5210A (is) 1997-04-15 1999-10-12 Notkun á fáliðupróteini brjóskundirstöðuefnis viðmeðhöndlun á liðagigt
NO995004A NO995004L (no) 1997-04-15 1999-10-14 Anvendelse av bruskoligometrisk matriksprotein for behandling av reumatoid artritt
US09/750,208 US20010002392A1 (en) 1997-04-15 2000-12-28 Treatment of rheumatoid arthritis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9701409A SE9701409D0 (sv) 1997-04-15 1997-04-15 Treatment of rheumatoid arthritis

Publications (1)

Publication Number Publication Date
SE9701409D0 true SE9701409D0 (sv) 1997-04-15

Family

ID=20406587

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9701409A SE9701409D0 (sv) 1997-04-15 1997-04-15 Treatment of rheumatoid arthritis

Country Status (21)

Country Link
EP (1) EP1019078B1 (sv)
JP (1) JP2001520647A (sv)
KR (1) KR20010006352A (sv)
CN (1) CN1260721A (sv)
AT (1) ATE245438T1 (sv)
AU (1) AU746221B2 (sv)
BR (1) BR9808591A (sv)
CA (1) CA2286791A1 (sv)
DE (1) DE69816634T2 (sv)
EE (1) EE9900464A (sv)
HU (1) HUP0002231A3 (sv)
ID (1) ID24561A (sv)
IL (1) IL132354A0 (sv)
IS (1) IS5210A (sv)
NO (1) NO995004L (sv)
NZ (1) NZ338084A (sv)
PL (1) PL336163A1 (sv)
SE (1) SE9701409D0 (sv)
SK (1) SK141399A3 (sv)
TR (1) TR199902564T2 (sv)
WO (1) WO1998046253A1 (sv)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849594B1 (en) * 1999-06-30 2005-02-01 John Lawler Purification and use of human recombinant cartilage oligomeric matrix protein
SE9904236D0 (sv) 1999-11-22 1999-11-22 Ana Mar Diagnostics Ab Immunoassay
KR100429288B1 (ko) * 2001-11-23 2004-04-29 장오기계 주식회사 전사인쇄장치
CN100417415C (zh) * 2006-06-28 2008-09-10 文彦春 浸润治疗关节炎的药物
DK2867679T3 (en) 2012-06-28 2018-08-13 Nordic Bioscience As DETERMINATION OF PATHOLOGICAL SHOWER COMPOSITION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5872094A (en) * 1993-01-06 1999-02-16 The General Hospital Corporation Method for attaching cartilaginous tissue, cartilage matrix protein or link protein to a surface

Also Published As

Publication number Publication date
DE69816634T2 (de) 2004-06-03
EP1019078A1 (en) 2000-07-19
IS5210A (is) 1999-10-12
AU746221B2 (en) 2002-04-18
TR199902564T2 (xx) 2000-02-21
ATE245438T1 (de) 2003-08-15
JP2001520647A (ja) 2001-10-30
CN1260721A (zh) 2000-07-19
EP1019078B1 (en) 2003-07-23
BR9808591A (pt) 2000-05-23
EE9900464A (et) 2000-04-17
KR20010006352A (ko) 2001-01-26
CA2286791A1 (en) 1998-10-22
NO995004D0 (no) 1999-10-14
ID24561A (id) 2000-07-27
PL336163A1 (en) 2000-06-05
HUP0002231A2 (hu) 2000-11-28
IL132354A0 (en) 2001-03-19
NO995004L (no) 1999-10-14
AU7093898A (en) 1998-11-11
SK141399A3 (en) 2000-08-14
DE69816634D1 (de) 2003-08-28
HUP0002231A3 (en) 2002-09-30
WO1998046253A1 (en) 1998-10-22
NZ338084A (en) 2001-07-27

Similar Documents

Publication Publication Date Title
NO20006718L (no) Proteaseinhibitorer
EE03969B1 (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
HK1049103A1 (zh) 含有利托那韋(abt-538)並與茚地那韋(mk-639)結合藥物的組合物以及他們在治療艾滋病中的用途
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
BR9804437A (pt) Compostos para a osteoporose
DE69426471D1 (de) Verwendung von Sulodexid und von Arzneimitteln, die dieses enthalten, zur Behandlung der diabetischen Nephropathie
MY104129A (en) Treatment of arthritis.
SE9701409D0 (sv) Treatment of rheumatoid arthritis
BR9814945A (pt) Utilização de fanquinona para o tratamento de doença de alzheimer, composição farmacêutica e kit
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE254595T1 (de) 2-amino-6-methyl-7-acetyl-tetralin und pharmazeutische zusammensetzungen zur vorbeugung und therapeutischen behandlung von entzündlichen und/oder autoimmunkrankheiten
GR3033698T3 (en) Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections.
WO2001014576A8 (en) Process and intermediates for the preparation of isoxazolecaroxamides and analogues
BR0111852A (pt) Nova interferona para o tratamento de esclerose múltipla
ATE291087T1 (de) Il-6 mutein
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
BR0010338A (pt) Composto enanciomericamente enriquecido, composição farmacêutica, método para tratar uma doença ou condição mediada por cck-a, uso de um composto, e, processo para a preparação de um composto
OA09197A (fr) "Peptides SDK, leur procédé de préparation ainsi que des compositions thérapeutiques en contenant".
BR9906931A (pt) Triazepinonas, processo para sua preparação e sua aplicação terapêutica
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
AR002956A1 (es) Proteinas utiles para el tratamiento de la obesidad y de trastornos relacionados con ella, proceso para obtenerlas y composiciones farmaceuticasque las contienen.
UA30874A (uk) Спосіб профілактики полігіпомікроелементозу
MX9800686A (es) Nueva proteina hmw humana mp52s.
BR9812265A (pt) Uso de análogos de gaba, tais como gabapentina, na fabricação de um medicamento para o tratamento de doenças inflamatórias.